Holen Sie sich die Stockscreener-App
1.53
0.66%
0.01
Handel nachbörslich:
1.58
0.05
+3.27%
Schlusskurs vom Vortag:
$1.52
Offen:
$1.53
24-Stunden-Volumen:
322.97K
Relative Volume:
1.03
Marktkapitalisierung:
$136.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$1.60M
KGV:
-3.825
EPS:
-0.4
Netto-Cashflow:
$-62.91M
1W Leistung:
-4.97%
1M Leistung:
+6.99%
6M Leistung:
-17.74%
1J Leistung:
-17.30%
1-Tages-Spanne:
$1.50
$1.59
1-Wochen-Bereich:
$1.44
$1.62
52-Wochen-Spanne:
$1.35
$3.0301
Compugen Ltd Stock (CGEN) Company Profile
Vergleichen Sie CGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
1.53 | 136.99M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2020-05-26 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-05-13 | Eingeleitet | Stifel | Buy |
| 2020-05-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-04-22 | Eingeleitet | ROTH Capital | Buy |
| 2020-03-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-03-29 | Eingeleitet | Oppenheimer | Outperform |
| 2016-02-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2015-10-15 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-23 | Fortgesetzt | Jefferies | Buy |
| 2015-04-21 | Eingeleitet | Oppenheimer | Outperform |
| 2014-02-07 | Eingeleitet | MLV & Co | Buy |
| 2009-12-28 | Bestätigt | Cantor Fitzgerald | Buy |
| 2009-07-29 | Eingeleitet | Cantor Fitzgerald | Buy |
Alle ansehen
Compugen Ltd Aktie (CGEN) Neueste Nachrichten
Astrazeneca Plc ADR (AZN-Q) QuotePress Release - The Globe and Mail
Gilead Sciences Inc (GILD-Q) QuotePress Release - The Globe and Mail
Compugen (CGEN) Stock Surges Amid Biotech Industry Movement - GuruFocus.com
Connor Clark & Lunn Investment Management Ltd. Grows Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World
Compugen Bolsters Cancer Therapy Portfolio with New Patent - TipRanks
Compugen Secures Key Patent for Triple Combination Cancer Immunotherapy Through 2037 | CGEN Stock News - StockTitan
Compugen Ltd. (NASDAQ:CGEN) Holdings Raised by Oppenheimer & Co. Inc. - Defense World
Compugen (CGEN) Stock Dips Amidst Biotech Sector Movements - GuruFocus.com
Compugen Ltd. (NASDAQ:CGEN) Short Interest Down 18.1% in October - MarketBeat
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Yahoo Finance
Compugen (CGEN) Stock Declines Amidst Industry Downtrend - GuruFocus.com
Compugen Ltd. (NASDAQ:CGEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... - Yahoo Finance
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... By GuruFocus - Investing.com Canada
Compugen Reports Strong Q3 2024 Results and Progress - TipRanks
Compugen: Q3 Earnings Snapshot - The Washington Post
Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates - Yahoo Canada Finance
Compugen earnings beat by $0.11, revenue topped estimates - Investing.com India
Compugen Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Compugen to Participate in Stifel 2024 Healthcare Conference - StockTitan
Compugen (CGEN) to Release Quarterly Earnings on Tuesday - Defense World
Compugen (NASDAQ:CGEN) shareholder returns have been stellar, earning 204% in 1 year - Simply Wall St
Compugen Showcases Promising Data on Ovarian Cancer Therapy - TipRanks
Compugen's Cancer Drug Combo Shows 17.4% Response Rate in Ovarian Cancer Trial | CGEN Stock News - StockTitan
Short Interest in Compugen Ltd. (NASDAQ:CGEN) Decreases By 17.1% - MarketBeat
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - cnhinews.com
Compugen Gears Up to Report Q3 Earnings: Here's What to Expect - Yahoo Finance
Compugen to Present New Clinical Data at SITC 2024 - StockTitan
Compugen Ltd. (NASDAQ:CGEN) Shares Sold by Renaissance Technologies LLC - Defense World
Compugen’s stock rockets on deal with Gilead for anti-tumor drug - MSN
Compugen Ltd. (NASDAQ:CGEN) Sees Large Growth in Short Interest - Defense World
CompoSecure Inc (CMPO) Analyst Thoughts: How High Can It Go? - Stocks Register
Compugen Ltd. (NASDAQ:CGEN) Short Interest Update - Defense World
Compugen Shareholders Approve All Proposals - TipRanks
Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Compugen to Present at Single Cell Genomics 2024 Conference - StockTitan
Compugen Ltd (CGEN)’s Market Momentum: Closing Strong at 1.82, Down -7.61 - The Dwinnex
Compugen Ltd’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Compugen Ltd (CGEN) shows promising results - US Post News
Rothschild Investment LLC Buys Shares of 221,900 Compugen Ltd. (NASDAQ:CGEN) - Defense World
Finanzdaten der Compugen Ltd-Aktie (CGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):